Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for treatment of non–small-cell lung cancer (NSCLC). Treatment with pembrolizumab in NSCLC requires PD-L1 ...
In an extensive review, researchers explore ZBP1-mediated programmed cell death and its potential as a therapeutic target for systemic diseases Programmed cell death, or PCD, is an actively regulated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback